NASDAQ:TENX Tenax Therapeutics Q4 2025 Earnings Results & Report $1.42 -0.06 (-4.05%) Closing price 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.46%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tenax Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 10, 2026. The company reported EPS of -$0.38 versus the -$1.26 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 10, 2026TimeBefore Market Opens Tenax Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$1.26Beat/MissBeat by +$0.88One Year Ago EPSN/AEPS Beat Rate8 of last 8 quartersTenax Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tenax Therapeutics Q4 2025 Earnings FAQ Did Tenax Therapeutics beat earnings estimates for Q4 2025? Tenax Therapeutics (NASDAQ:TENX) reported earnings of -$0.38 per share for Q4 2025, beating the consensus estimate of -$1.26. The report was announced on Tuesday, March 10, 2026. Tenax Therapeutics Earnings HeadlinesPomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX3 hours ago | globenewswire.comTENX ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tenax Therapeutics, Inc. and Encourages Investors to Contact the Firm4 hours ago | globenewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 17 at 1:00 AM | Profits Run (Ad)TENX Shareholder Alert: December 28, 2026 Lead Plaintiff Deadline in Tenax Therapeutics, Inc. Securities Class Action - Contact SueWallStNovember 17 at 10:18 AM | globenewswire.comTENX Investors Have Rights - If You Lost Money Investing in Tenax Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your LossesNovember 16 at 8:16 PM | prnewswire.comDeadline Alert: Tenax Therapeutics, Inc. Investors Have Until December 28, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds InvestorsNovember 16 at 4:40 PM | globenewswire.comSee More Tenax Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email. Email Address About Tenax TherapeuticsTenax Therapeutics (NASDAQ:TENX) is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition involving elevated pressure in the lung’s blood vessels and impaired heart function. The company’s lead program is levosimendan, a drug being developed in different formulations for PH-HFpEF. Tenax has described its development program as including oral, intravenous and subcutaneous formulations. Levosimendan is approved for certain heart-failure uses in some countries, but Tenax is studying it for a different indication. Tenax Therapeutics is based in Morrisville, North Carolina, and its work centers on clinical development rather than marketing an established commercial product.View Tenax Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.